PrECOG 0905-Studie: Gefitinib vs. Midotuximab plus intensive Chemotherapie bei neu diagnostizierter FLT3-mutierter akuter myeloischer Leukämie – aml-hub.com
PrECOG 0905-Studie: Gefitinib vs.
Vollstaendiger Artikelinhalt
We summarize the key findings from the phase II PrECOG 0905 trial evaluating the efficacy of gilteritinib vs midostaurin in combination with intensive chemotherapy in patients with newly diagnosed FLT3-mutated AML.
Sản phẩm liên quan đến bài viết
Các sản phẩm này được tự động đối chiếu từ tiêu đề, tóm tắt và nội dung bài viết.
Câu hỏi thường gặp
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Gefitinib – Mua trực tuyến Lucius Gilteritinib – Mua trực tuyến GILLIDX Gilteritinib 40mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.